Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 762-772

  Bagnoli, Marina ^a   Balladore, Emanuela ^a,b   Luison, Elena ^a   Alberti, Paola ^a   Raspagliesi, Francesco ^a   Marcomini, Barbara ^a   Canevari, Silvana ^a   Mezzanzanica, Delia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEATH RECEPTOR; FAS ANTIBODY; FAS ANTIGEN; PROTEIN P53;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE MUTATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MONOTHERAPY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCITIC FLUID; BLOTTING, WESTERN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL LINE, TUMOR; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; CYTOCHROMES C; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOPRECIPITATION; MEMBRANE MICRODOMAINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847419866     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0357     Document Type: Article

References (35)

1. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
2. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
3. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-14.
4. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22: 7414-30.
5. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
6. Mezzanzanica D, Balladore E, Turatti F, et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 2004;10: 5202-14.
7. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
8. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002;21:8786-803.
9. Canevari S, Gariboldi M, Reid JF, et al. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 2006;60:19-37.
10. Lavarino C, Pilotti S, Oggionni M, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000;18:3936-45.
11. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003; 21:285-91.
12. Soussi T. p53 mutations and resistance to chemotherapy: a stab in the back for p73. Cancer Cell 2003;3:303-5.
13. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/ Fas) gene in response to DNA damage by anticancer drugs. J Exp Mad 1998; 188:2033-45.
14. Longley DB, Allen WL, McDermott U, et al. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 2004;10:3562-71.
15. Muller M, Schilling T, Sayan AE, et al. TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-77.
16. Gressner O, Schilling T, Lorenz K, et al. TAp63α induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24:2458-71.
17. Siervo-Sassi RR, Marrangoni AM, Feng X, et al. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 2003;190:61-72.
18. Vignati S, Codegoni A, Polato F, Broggini M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002;38:177-83.
19. Britten RA, Perdue S, Eshpeter A, Merriam D. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. Oncol Rep 2000;7:821-5.
20. Drewinko B, Loo TL, Brown B, et al. Combination chemotherapy in vitro with Adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1976;1: 187-95.
21. Bagnoli M, Tomassetti A, Figini M, et al. Down-modulation of caveolin-1 expression in human ovarian carcinoma is directly related to a-folate receptor overexpression. Oncogene 2000;19:4754-63.
22. Ozoren N, Kim K, Burns TF, et al. The caspase 9 inhibitor z-LEHD-fmk protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:6259-65.
23. Riesbeck K. Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes. Anticancer Drugs 1999;10:219-27.
24. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
25. Eramo A, Sargiacomo M, Ricci-Vitiani L, et al. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type I cells. Eur J Immunol 2004;34:1930-40.
26. Milner AE, Palmer DH, Hodgkin EA, et al. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ 2002;9:287-300.
27. McDermott U, Longley DB, Galligan L, et al. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005;65:8951-60.
28. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416: 560-4.
29. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-73 cross-talk in vivo. Clin Cancer Res 2005;11:8372-83.
30. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10.
31. Kakinuma C, Takagaki K, Yatomi T, et al. Acute toxicity of an anti-Fas antibody in mice. Toxicol Pathol 1999;27:412-20.
32. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
33. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Mad 1999; 5:157-63.
34. Ichikawa K, Yoshida-Kato H, Ohtsuki M, et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000;12:555-62.
35. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997;99:403-13.